Mitochondria: the target for ischemia-reperfusion injury and cardioprotection
Mitochondria are effectors of both ischemia-reperfusion injury (IRI) and cardioprotection. As pointed out 30 years ago by Jennings and Ganote [1] , the heart is strictly aerobic and consequently extremely vulnerable to a decrease in oxygen supply. Thus, ischemia causes profound and immediate mitochondrial derangements. These include cessation of ATP synthesis, inhibition of respiration, and a drop in ΔΨ. This is accompanied during ischemia by cellular changes, especially an increase in Ca 2+ and phosphate, and, during reperfusion, by large increases in reactive oxygen species (ROS) originating from the respiratory chain [2, 3] . Together, these factors promote opening of the mitochondrial permeability transition (MPT), a high-conductance pore in the inner mitochondrial membrane, which is the main cause of necrotic cell death in IRI [4] [5] [6] [7] [8] . Consequently, as pointed out by Weiss et al. [4] , cardioprotection by preconditioning or postconditioning must ultimately involve the prevention of MPT. In addition to their role as mediators of cell death, mitochondria have been shown to be major effectors of diverse self-defense mechanisms, including ischemic pre-and post-conditioning [7, [9] [10] [11] . These and other conditioning protocols have been shown to require opening of the mitochondrial ATP-sensitive K + channel (mitoK ATP ) and inhibition of MPT opening. Since cardioprotection involves both mitoK ATP opening and a decrease in MPT opening, it is reasonable to hypothesize that these two phenomena are part of the same signaling pathway. Indeed, this connection has been demonstrated [12] , and will be discussed in this review. This review describes our current understanding of the signaling mechanisms that originate at plasma membrane receptors, go to mitochondria, and terminate with MPT inhibition. For space reasons, we have not discussed mechanisms for the prevention of apoptosis. For different perspectives, readers are referred to excellent reviews by other authors [13] [14] [15] [16] [17] [18] .
Receptor-mediated signaling to open mitoK ATP

Gi-protein coupled receptor (GPCR) pathways
Ischemic preconditioning (IPC) and ischemic postconditioning are receptor-mediated processes that are triggered by GPCR agonists released by the ischemic heart, primarily bradykinin, opioid peptides, and adenosine [19] . Other GPCR ligands, including acetylcholine, catecholemines, endothelin, and angiotensin II, are also cardioprotective [20] [21] [22] [23] [24] , but they were found not to be physiological triggers of IPC [14] . A composite diagram of the GPCR signaling pathways is given in Fig. 1 . GPCR signaling has been extensively studied by Downey and Cohen and their coworkers, and is the subject of an excellent review by these authors [14] . It should be emphasized that each G i -coupled receptor ligand triggers its own unique signaling cascade. Opioids and acetylcholine instigate transactivation of the epidermal growth factor receptor (EGFR), leading to downstream activation of phosphatidylinostitol 3-kinase (PI3-K) and Akt. Bradykinin also induces activation of PI3-K and Akt, but without transactivation of EGFR. These two pathways then converge and ultimately lead to mitoK ATP opening and production of ROS. The adenosine signaling pathway has not yet been fully characterized. MitoK ATP opening is not involved during the trigger phase of adenosine preconditioning (i.e., when 5-HD administration brackets adenosine perfusion) [25] , but mitoK ATP opening is required during the mediator phase (i.e., when 5-HD administration precedes ischemia) [26] [27] [28] [29] .
Protection afforded by all of the trigger substances is blocked by PKC inhibitors, and PKC, probably PKCɛ, is thought to be a common target of cardioprotective signaling [14] . It has been difficult to localize the critical PKCɛ, because multiple PKCɛ isoforms participate in cardioprotection [30] . In ouabain signaling, PKCɛ acts proximally in conjunction with EGFR transactivation [31] . The adenosine A1 receptor is believed to directly stimulate PLC and PLD to activate PKC [21] . These PKCs are cytosolic. As discussed below, two PKCɛ isoforms regulate mitoK ATP and MPT at the level of the inner mitochondrial membrane [32] . Thus, the physiological effect of PKCɛ activation depends entirely on its location and not on its biochemistry, which appears to be invariant.
Non-GPCR pathways of protection -digitalis
Cardiac glycosides are classic inhibitors of the plasma membrane Na + /K + -ATPase, but this enzyme also has important non-canonical functions that are triggered by digitalis. Thus, ouabain interaction with the Na,K-ATPase activates src kinase, causing formation of a "binary receptor" that phosphorylates and assembles other proteins into signaling modules that transmit signals to intracellular compartments [33, 34] . Ouabain signaling has been shown to depend on mitoK ATP opening and mitochondrial ROS production [35] . Ouabain is cardioprotective in rat heart [31, 36, 37] , and this cardioprotection is blocked by the mitoK ATP blocker 5-hydroxydecanoate (5-HD), the ROS scavenger N-2-mercaptopropionylglycine (MPG), and the src kinase inhibitor PP2 [36] . It is interesting to note that, whereas inhibition of the pump and consequent increase in intracellular Na + and Ca 2+ is required for positive inotropy, ouabain cardioprotection occurs at doses (about 10 μM in rat) that do not produce significant enzyme inhibition [37] or increased contractility [31, 36, 37] . These distinctions further emphasize the dissociation of the pumping and signaling functions of Na,K-ATPase. Ouabain cardioprotection does not depend on guanylyl cyclase or PKG activities, showing that this signaling pathway differs from that triggered by GPCR agonists [36] . Ouabaininduced inotropy also requires mitoK ATP opening and ROS production [36, 38] . The rat heart Na,K-ATPase exhibits a low sensitivity to cardiac glycosides; however, we have observed qualitatively similar phenomena in the ouabain-sensitive rabbit heart. Thus, cardioprotection occurs at lower ouabain doses than those required for inotropy, and both cardioprotection and inotropy require mitoK ATP opening (S. Pierre, unpublished data).
From receptor to mitochondria by signalosomes
We propose that cardioprotective signals are transmitted to mitochondria by signalosomes, which are vesicular, multimolecular signaling complexes that are assembled in caveolae and deliver signals Fig. 1 . GPCR-mediated signaling to mitochondria. Occupation of the GPCR leads to activation of PI3-kinase, phosphorylation of phosphatidylinositol bisphosphate, and activation of the phosphatidylinositol-dependent kinases (PDKs) [128] . PDKs then phosphorylate Akt, which initiates the remainder of the cytosolic signaling pathway: endothelial nitric oxide synthase (eNOS) is phosphorylated, leading to production of NO. NO stimulates guanylyl cyclase, and the cGMP produced activates protein kinase G (PKG) [129] , which causes mitoK ATP opening [62, [130] [131] [132] .
to the mitochondrial outer membrane (MOM) [39] . A diagram of the signalosome hypothesis is presented in Fig. 2. 
Rationale
Signaling cascades such as the one portrayed in Fig. 1 must occur rapidly and precisely. We consider it unlikely that these spatiotemporal requirements can be met by random diffusional collisions. Cytosolic proteins are extensively hydrated, and the organization of this water causes a phase separation from bulk cytosolic water. Minimization of the phase boundary, in turn, causes proteins to coalesce within their common hydration phase [40] . If the proteins of the cardioprotective signaling pathway were randomly distributed in the cytosol, they too would coalesce within the hydration phase, with losses of directionality and specificity. Accordingly, we suggest that the signaling cascade is compartmentalized to promote metabolic channeling and that the entire reaction sequence moves through the cytosol as a unit. This hypothesis agrees with and extends the proposal by Ping and coworkers [41, 42] that intracellular signaling involves assembly and regulation of multiprotein complexes.
The signalosome hypothesis
Upon activation, GPCR migrate to caveolae, where caveolins organize and compartmentalize receptors and signaling molecules [43] [44] [45] [46] [47] [48] [49] . Caveolae are 50-100 nm membrane invaginations that are rich in cholesterol, sphingolipids, and caveolin proteins [50] . EGFR, the Src family of tyrosine kinases, G-protein α-subunits, PKC isoforms, and transporters such as the Na/K-ATPase have been found to associate with caveolins, which also regulate the activity of many of these proteins [50] [51] [52] [53] [54] [55] [56] . Caveolar assembly of the signaling platform is followed by budding off and internalization [57] . Receptor endocytosis has been observed for both GPCRs [45, 47, [58] [59] [60] and the α1-subunit of Na,K-ATPase [61] . We propose, therefore, that the receptor-specific signaling platform is assembled in caveolae, then separates and internalizes as a signalosome. The signalosome migrates via the cytoskeleton to mitochondria, where it binds to receptors on the MOM, designated in Fig. 2 as R1 (for GPCR-induced signalosomes) and R2 (for ouabain-induced signalosomes). The terminal kinase of the signalosome phosphorylates its specific receptor, which causes the signal to be transmitted across the MOM and intermembrane space to PKCɛ1 on the mitochondrial inner membrane. This is followed by the intramitochondrial signaling pathway described in Section 4 and Fig. 4 .
Experimental evidence for signalosome-mediated mitoK ATP opening
We developed protocols for purifying signalosomes from hearts subjected to various preconditioning or postconditioning protocols and then assayed their functional activity [39] . When the signalosome fractions were added to mitochondria from untreated hearts, they caused mitoK ATP opening, as shown in Fig. 3 . Based on the finding that functionally active signalosomes were obtained from hearts exposed to bradykinin, ouabain, ischemic preconditioning, and ischemic postconditioning (Fig. 3) , we conclude that this is a general mechanism of signal transmission. Signalosome preparations also inhibited MPT when added to mitochondria from untreated hearts. The signalosomes were dissolved by the cholesterol binding agent methyl-β-cyclodextrin and were resistant to Triton X-100. These properties support their origin in caveolae. Electron microscopy reveals that the signalosomes are 100-140 nm in diameter and can be decorated with immunogold labeled caveolin 3 antibodies [39] . The signalosome induced by bradykinin stimulation contains eNOS, guanylyl cyclase, and cGMP-dependent protein kinase (PKG), and we were able to demonstrate the participation of each of these enzymes in the mitoK ATP assay when proper substrates were supplied (Quinlan and Garlid, unpublished).
Signalosomes phosphorylate MOM receptors
As shown in Fig. 3 , addition of signalosomes from preconditioned hearts to mitochondria from non-preconditioned hearts results in activation of the mitoK ATP . Activity of signalosomes induced by GPCRmediated protection (bradykinin, IPC, and postconditioning) is inhibited by KT5823, and we conclude that GPCR signalosomes use PKG as the terminal kinase that interacts with mitochondria. In contrast, the activity of signalosomes induced by ouabain is not inhibited by KT5823, in agreement with the finding that KT5823 does not block protection by ouabain [36] . Activity of the ouabain signalosome is inhibited by preincubation with ɛV 1-2 and PP2 (both Fig. 2 . Signal transmission by signalosome. It is proposed that interaction of bradykinin (and other GPCR agonists) or ouabain with their plasma membrane receptors induces formation of a vesicular caveolar signaling platform (signalosome) that phosphorylates rreceptors (R1 and R2) on the mitochondrial outer membrane (MOM). The terminal kinase of the bradykinin signalosome is PKG. The terminal kinases of the ouabain signalosome are PKCɛ and Src kinase. Following phosphorylation of the MOM receptor, the signal is transmitted across the intermembrane space to activate PKCɛ on the mitochondrial inner membrane. PKCɛ, in turn opens mitoK ATP by a phosphorylation reaction [32] . Fig. 3 . Signalosomes from treated hearts induce mitoK ATP opening in mitochondria from untreated hearts. Shown are changes in "MitoK ATP activity (%)" when signalosome fractions from rat hearts treated with bradykinin, ouabain, ischemic preconditioning, or ischemic postconditioning were added to assay mitochondria from untreated rat hearts. Ischemic preconditioning consisted of two 5 min ischemia-reperfusion cycles, and ischemic postconditioning consisted of six 10 s cycles of ischemia-reperfusion. Also shown are the effects of PP2A (11 ng/mL) and KT5823 ("KT", 0.5 μM) added to the assay. Note that PP2A cannot cross the MOM of intact mitochondria, so its effect is on the MOM. Data are averages ± SD of 3 to 4 independent experiments. The figure is from Quinlan et al. [39] .
are required), indicating that the terminal kinases are PKCɛ and Src kinase. We have found that recombinant PKG [32, 62] or recombinant PKCɛ plus Src (Quinlan and Garlid, unpublished) can also induce mitoK ATP opening in isolated mitochondria.
That the signalosomes interact with the MOM was demonstrated by the finding that neither the signalosomes nor the recombinant terminal kinases induce mitoK ATP opening in mitoplasts lacking the MOM [32, 39] . That signalosomes interact by phosphorylation was demonstrated by the finding that activity was blocked in the presence of the Ser/Thr phosphatase PP2A (Fig. 3) . The ouabain signalosome was also blocked by tyrosine phosphatase, confirming the action of its Src kinase.
We have not yet determined the molecular identity of R1. R2 is an endogenous MOM MAP kinase, as revealed by Western blot showing increased phosphorylation of p38 MAPK (Thr 180/Tyr 182) after the heart was treated with ouabain and functional studies showing that the MAP kinase inhibitor SB203580 blocked mitoK ATP opening by the ouabain signalosome (Quinlan and Garlid, unpublished studies).
Signal transmission from MOM to PKCɛ1
Signalosome-dependent mitoK ATP opening is also blocked by the PKCɛ inhibitors chelerythrine and ɛV 1-2 [62] , confirming a role for PKCɛ ("PKCɛ1" in Fig. 2 ), which is discussed in the next section. Signaling from R1 or R2 to PKCɛ1 is not prevented by MPG, and therefore this step does not involve ROS. This is all we know at this stage about the nature of the link between the MOM receptors and PKCɛ1.
Intramitochondrial signaling
The diagram in Fig. 4 summarizes several years of studies on intramitochondrial signaling [12, 32, 39, [62] [63] [64] [65] [66] . The primary function of this pathway is to inhibit MPT opening, which is widely considered to be the cause of cell death after ischemia-reperfusion [5, 6, 11] .
4.1.
Step one -opening mitoKATP by activation of PKCɛ1
Ischemic preconditioning, ischemic postconditioning, and pharmacological preconditioning by plasma membrane receptor agonists cause mitoK ATP opening by activating a PKCɛ that is constitutively expressed in mitochondria and associated with the mitochondrial inner membrane [64] . The PKCɛ-specific peptide agonist ΨɛRACK and the PKCɛ agonists H 2 O 2 , NO, and phorbol 12-myristate 13-acetate (PMA) each open mitoK ATP (see Fig. 5 ) [32] . That these agents were acting via PKCɛ ("PKCɛ1" in Fig. 4 ) was verified by showing that the PKCɛ-specific binding antagonist ɛV 1-2 blocked all four modes of PKCɛ activation of mitoK ATP but did not block mitoK ATP opening by diazoxide [32, 64] . Neither the PKCδ-specific peptide antagonist, δV 1-1 nor a scrambled analog of ɛV 1-2 had any effect on H 2 O 2 -dependent mitoK ATP opening. Moreover, the PKC inhibitor Gö6983, which inhibits PKCα, PKCβ, PKCγ, and PKCζ, did not block PKCɛ-dependent mitoK ATP opening, excluding a role for these isoforms [62] .
Jaburek et al. [64] showed that ΨɛRACK and ɛV 1-2 open mitoK ATP in liposomes reconstituted with partially purified mitoK ATP . Thus, mitoK ATP and PKCɛ copurify and remain associated during multiple purification steps carried out in the presence of Triton X-100. This, together with the finding that PKCɛ remains associated with mitochondria in mitoplasts [12] , suggests that PKCɛ and mitoK ATP are part of a functional complex. When given access in mitoplasts to the mitochondrial inner membrane ("MIM"), PP2A prevented mitoK ATP -dependent swelling induced by PKCɛ agonists [32] , and we conclude that PKCɛ-dependent mitoK ATP opening requires phosphorylation, perhaps of mitoK ATP itself.
PKCɛ requires anionic phospholipids for activity, a requirement met in this case by cardiolipin, which is abundant in mitochondria. PKCɛ is activated physiologically by diacylglycerol (or phorbol ester) or by a sulfydryl oxidizing agent, such as H 2 O 2 [67] or NO [32] . PMA or H 2 O 2 open up one of the two zinc fingers in PKCɛ [68, 69] . ΨɛRACK, PMA, H 2 O 2 , or NO cause conformational changes that expose the substrate domain on PKCɛ and cause its binding to its RACK (receptor for activated C kinase [70] ). ΨɛRACK is a PKCɛ-specific peptide agonist that acts by regulating intramolecular PKCɛ binding, and ɛV 1-2 is a PKCɛ-specific peptide antagonist that acts by preventing protein-protein interactions between PKCɛ and its binding protein [70] [71] [72] . Murriel and Mochly-Rosen [73] found that ΨɛRACK protected cardiac cells from ischemic damage, whereas ɛV 1-2 caused a loss of protection. Fig. 4 . The intramitochondrial signaling pathways. The pathways leading to mitoK ATP opening, ROS production, and MPT inhibition are shown. Signals arising from Gicoupled receptors are delivered to mitochondria via the terminal kinase PKG. Signals arising from ouabain action upon the Na-K ATPase are delivered to mitochondria via two terminal kinases, PKCɛ and Src. The terminal kinases are localized in the signalosomes. PKG phosphorylates an unknown MOM receptor, "R1", whereas PKCɛ and Src act in conjunction to activate a distinct MOM receptor, "R2". These MOM receptors transmit the signal by an unknown mechanism to PKCɛ1 located at the inner membrane. The activated PKCɛ1 phosphorylates and opens mitoK ATP . PKCɛ1 activity is likely to be counteracted physiologically by Ser/Thr protein phosphatases (PPase) such as PP2A. MitoK ATP opening via PKCɛ1 or by K ATP channel openers such as diazoxide causes K + uptake, increased matrix pH, and increased ROS production from ComplexI.
ROS produced by mitoK ATP activity now diffuses and activates both PKCɛ1 and PKCɛ2. PKCɛ2 inhibits MPT, thus reducing cell necrosis and infarct size. The figure is from Costa and Garlid [32] . 
4.2.
Step two -mitochondrial K + uptake and its consequences Uptake of K + salts and osmotically obligated water leads to increased matrix volume ("ΔV" in Fig. 4) , which is the basis of the light scattering (LS) assay for mitoK ATP activity [65] . LS is the only practical method to study this process in isolated mitochondria, because mitoK ATP -dependent K + flux is rapid (t 1/2 ∼ 30 s) and small in magnitude. This technique has been successfully employed by several laboratories to measure K + flux in mitochondria [76] [77] [78] [79] [80] .
MitoK ATP -dependent matrix alkalinization plays an essential role in intramitochondrial signaling. It causes Complex I to produce increased amounts of superoxide and its products, H 2 O 2 and hydroxyl anion radical [66] . As seen below, the ROS produced by this mechanism play two important roles in cardioprotection, through their ability to activate PKCɛ.
We note that each of the consequences of mitoK ATP opening is due specifically to the increased K + influx. Thus, valinomycin (approximately 1 pmol/mg mitochondria) duplicates the effects of KCO on K + uptake, respiration, matrix alkalinization, volume increase, ROS production, and MPT inhibition [12, 65, 66] .
4.3.
Step three -activation of PKCɛ by endogenous ROS
ROS activation of PKCɛ2 and inhibition of MPT
The increased ROS activates a second mitochondrial PKCɛ, "PKCɛ2" in Fig. 4 , which inhibits the mitochondrial permeability transition ("MPT") in a phosphorylation-dependent reaction [12] . H 2 O 2 and NO, but not superoxide, also activate PKCɛ2 and inhibit MPT [12, 32] . The dichotomy between protective and damaging ROS was strikingly demonstrated in an experiment in which 100 μM H 2 O 2 plus 2 μM free Ca 2+ were used to induce MPT opening in heart mitochondria. This ROS-induced MPT opening was inhibited when the mitochondria were first conditioned with 2 μM H 2 O 2 [12] . Thus, cardioprotective mitoK ATP opening leads to inhibition of MPT, and, therefore, to reduction of cell death after ischemia-reperfusion injury [5, 6, 11] . The evidence for two distinct mitochondrial PKCɛ is that the specific agonist ΨɛRACK can activate PKCɛ1and open mitoK ATP , but it cannot activate the PKCɛ that regulates MPT [12] . This establishes a clear difference between the two PKCɛs. Our tentative explanation for the observation is that PKCɛ2 faces the matrix side of the inner membrane. ΨɛRACK is an anionic peptide that cannot enter the matrix, whereas ɛV 1-2 , which inhibits both PKCɛ1 and PKCɛ2, can readily enter the matrix.
ROS activation of PKCɛ1 and feedback mitoK ATP opening
The mitoK ATP -dependent increase in ROS plays an additional role in cardioprotection. Note in Fig. 4 that PKCɛ1 is bypassed when KCOs are administered to the heart; however, we have found that PKCɛ1 is soon activated by mitoK ATP -dependent ROS, leading to a persistent phosphorylation-dependent open state of mitoK ATP [32] . These data define a new, positive feedback loop for mitoK ATP opening, whose existence, which has been suggested by a number of authors [81] [82] [83] , means that mitoK ATP may be either upstream or downstream of PKCɛ, depending on the triggering stimulus. We suggest that feedback phosphorylation of mitoK ATP is the mechanism of memory, which is seen with all PC triggers [84, 85] . Thus, cardioprotective stimuli can be washed away from the system and the perfused heart remains protected from a major ischemic assault, thanks to phosphorylation of mitoK ATP . We infer, but have not demonstrated, that mitoK ATP opening is eventually reversed by an endogenous phosphatase ("PP2A" in Fig.  4) within the intermembrane space. For example, PP2A has been found in mitochondria where it is activated by proapoptotic factors [86] .
Intramitochondrial signaling and the literature
The model in Fig. 4 helps to support and extend results of previous studies. Jiang et al. [87] observed PKC and 5-HD regulation of the human cardiac mitoK ATP in lipid bilayers. Garg and Hu [88] showed that PKCɛ modulates mitoK ATP activity in cardiomyocytes and COS-7 cells. Penna et al. [89] demonstrated that protection by postconditioning involves a redox mechanism and persistent activation of mitoK ATP and PKC. Facundo et al. [80] showed that H 2 O 2 induces mitoK ATP activity in isolated mitochondria, but did not identify participation of PKCɛ. Zhang et al. [90] found that superoxide anion activated mitoK ATP in planar bilayers, and we showed that this effect is mediated, not by superoxide, but by H 2 O 2 acting indirectly via PKCɛ1 [32] . Sasaki et al. [91] suggested that NO may open mitoK ATP directly; however mitoK ATP opening by NO is blocked by ɛV 1-2 [32] , showing that NO opens mitoK ATP indirectly through PKCɛ1. Several authors have shown that exogenous and endogenous NO are cardioprotective and have attributed this effect to MPT inhibition [92] [93] [94] [95] . Brookes et al. [92] showed that NO inhibited MPT and cytochrome c release in isolated liver mitochondria. We showed that this effect occurs via activation of PKCɛ2 [32] . Korge et al. [96] found that diazoxide prevented MPT opening and cytochrome c loss, and that both effects were mimicked by the PKC activator PMA and blocked by 5-HD. Kim et al. [97] found that a cytosolic extract, together with cGMP and ATP, blocked MPT in isolated mitochondria, an effect that was blocked by PKG inhibition. Forbes et al. [98] and Pain et al. [85] found that N-acetylcysteine or MPG reversed the protective effect of diazoxide in perfused hearts. Our data suggests that blockade of protection occurred because mitoK ATP -dependent ROS was scavenged and unavailable to activate PKCɛ2 and inhibit MPT. Lebuffe et al. [81] found that PMA-induced protection was blocked by 5-HD and that this block was reversed by coadministration of H 2 O 2 and NO. This is also consistent with the model of Fig. 4 in that H 2 O 2 and NO can bypass the blocked mitoK ATP and act directly on PKCɛ2, thereby inhibiting MPT and protecting the heart.
Other mitochondrial mechanisms of cardioprotection
K ATP channel openers (KCO)
KCOs have been shown to be cardioprotective in all species examined [99, 100] . The ability of KCOs to open mitoK ATP in their therapeutic dose range was described in 1996 [101] . Diazoxide was 1000 times more potent in opening mitoK ATP than in opening sarcK ATP , making diazoxide a valuable tool to determine whether cardioprotection was mediated by the sarcolemmal or the mitochondrial K ATP channel. It was found that diazoxide was as effective as cromakalim in protecting the heart. Moreover, diazoxide protection, unlike that mediated by cromakalim, was not accompanied by APD shortening, thus demonstrating that cardioprotection was not due to sarcK ATP opening. These findings led to the hypothesis that mitoK ATP is the receptor that mediates the cardioprotective effects of KCOs [101, 102] . KCOs act on the regulatory sulfonylurea receptors (SUR) of K ATP channels. Pinacidil, cromakalim, and nicorandil are effective openers of cardiac K ATP through their action on SUR2A, but ineffective on pancreatic beta cell K ATP , which uses SUR1. Conversely, diazoxide is an effective opener of beta cell K ATP , but ineffective on the cardiac channel [101, 103] . All KCOs we have examined open mitoK ATP and protect the heart [65, 101, 102, [104] [105] [106] [107] [108] .
Glycogen synthase kinase-3β (GSK-3β)
The GSK-3β inhibitors lithium and SB 216763 are cardioprotective. IPC and diazoxide cause phosphorylation and inactivation of GSK-3β [83, 109] , suggesting that GSK-3β may be downstream of mitoK ATP . Inhibition of GSK-3β has no effect on MPT opening in isolated mitochondria [32] , suggesting that the GSK isoform that interferes with cardioprotection resides outside of mitochondria. Importantly, cardioprotection by GSK-3β inhibition is blocked by 5-HD [110] , indicating that the ultimate deleterious effect of GSK-3β activity may be to cause mitoK ATP inhibition.
Amobarbital
Amobarbital, administered 1 min before 25 min global ischemia, is cardioprotective in rat, causing marked improvement of contractile function and reduction of infarct size [111] . Amobarbital is a shortacting barbiturate that is a classic, reversible inhibitor of Complex I at the rotenone site. Amobarbital treatment was associated with preservation of cytochrome c [111] , which is otherwise released after ischemia-reperfusion, due in part to oxidative degradation of cardiolipin [112] . Cardioprotection by amobarbital is consistent with the authors' overall hypothesis that ROS arising from Complex III during ischemia causes mitochondrial damage that contributes to myocardial injury during reperfusion [113] .
Bromoenol lactone (BEL)
BEL, administered before global ischemia, is cardioprotective in rat [114] and rabbit [115] , causing marked reduction of infarct size. BEL is a specific inhibitor of calcium-independent phospholipase A(2) (iPLA2), which is the major phospholipase A(2) in myocardium and is present in heart mitochondria [115] . Ischemia causes fatty acid accumulation in the heart, caused by phospholipase-mediated degradation of membrane phospholipids [112, 116, 117] . Protection by BEL was reversed, in both rat and rabbit hearts, by the simultaneous perfusion of 5-HD, implying participation of mitoK ATP .
Hydrogen sulfide
H 2 S, administered before global ischemia, is cardioprotective in rat [118] [119] [120] . H 2 S is synthesized in the heart and other tissues by cystathionine λ-lyase. Cytoplasmic [H 2 S] is determined by the balance between its constitutive production and its oxidation by mitochondria. When tissue oxygen levels fall, H 2 S oxidation decreases, and [H 2 S] increases, and Olson et al. [121] consider H 2 S to be the oxygen sensor of cells. Protection by H 2 S was abolished by chelerythrine, implicating participation of PKC [119] . Infarct size reduction by H 2 S was also abolished by glibenclamide and 5-HD, implicating participation of mitoK ATP in H 2 S protection [120] . H 2 S increased the open probability of sarcolemmal K ATP in cardiomyocytes [122] and may have a similar effect on mitoK ATP .
Mitochondrial aldehyde dehydrogenase (ALDH2)
An activator of ALDH2, administered before global ischemia, is cardioprotective in rat, causing marked reduction of infarct size [123] . This recent discovery was the result of a directed proteomic search. The authors speculate that protection by ALDH2 activation is due to its metabolism of cytotoxic aldehydes, such as 4-hydroxynonenol.
Ca
2+
-activated mitochondrial K + channel (mitoK Ca )
NS1619, an activator of the large conductance mitoK Ca is cardioprotective in guinea pig, and protection is blocked by the inhibitor paxilline [124] [125] [126] . Sato et al. [127] found that there was no cross-talk between mitoK ATP and mitoK Ca -that is, paxilline blocked effects of NS1619 but not diazoxide, and 5-HD blocked effects of diazoxide but not NS1619. Cao et al. [125] observed similar absence of cross-talk in cardioprotection experiments. The latter findings suggest distinct channels with distinct pharmacology and suggest that these two channels constitute alternative mechanisms for raising matrix K + and generating ROS.
Summary
Recent years have brought robust advances in our understanding of cardiac signal transduction during cardioprotection against ischemia-reperfusion and the pivotal role of mitochondria in these processes. This review exposes our current understanding of the mechanistic link between plasma membrane receptors and MPT, the ultimate mitochondrial target of cardioprotection. We suggest that interaction of the cardioprotective ligand with its receptor induces the formation of a signaling platform that is scaffolded by caveolins, that contains the activated enzymes of the pathway, and that is delivered to mitochondria as a signalosome. We believe that the signalosome mechanism [39] provides a means to resolve the mystery of receptor-specificity described by Downey et al. [14] :
"It is still a mystery how identical Gi proteins, when activated by binding of the different agonists to their individual receptors, can initiate such distinct signaling pathways."
This review also points to several areas that require further investigation as to how signalosomes are directed to mitochondria, how cytoskeleton is involved, and what receptors are involved at the mitochondrial level. Even in light of these questions, the elucidation of the interactions among signaling components and mitochondria is a valuable tool for understanding the molecular controls in the decision between cell survival and cell death.
